---
title: "Chinese Pharma Experts Discuss Innovative Drugs’ Full Chain From R&D to Market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295064772.md"
description: "(Yicai) Aug. 6 -- This episode of Growth Tech Talks focuses on high-quality development and global breakthroughs in the innovative pharmaceutical industry, exploring the full chain of innovative drug R&D, clinical trials, CRO services, and commercialization. It features guests including RemeGen’s Chairman Wang Weidong, InnoCare Pharma’s Chairwoman and CEO Jasmine Cui, Dizal Pharmaceutical’s Chair and CEO Zhang Xiaolin, Shanghai Medicilon’s Chair and CEO Chen Chunlin, and Guotai Haitong Securities’ Chief Flobal Healthcare Analyst Yu Wenxin."
datetime: "2026-08-06T06:33:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295064772.md)
  - [en](https://longbridge.com/en/news/295064772.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295064772.md)
generator: "portal-rs"
---

# Chinese Pharma Experts Discuss Innovative Drugs’ Full Chain From R&D to Market

(Yicai) Aug. 6 -- This episode of Growth Tech Talks focuses on high-quality development and global breakthroughs in the innovative pharmaceutical industry, exploring the full chain of innovative drug R&D, clinical trials, CRO services, and commercialization. It features guests including RemeGen’s Chairman Wang Weidong, InnoCare Pharma’s Chairwoman and CEO Jasmine Cui, Dizal Pharmaceutical’s Chair and CEO Zhang Xiaolin, Shanghai Medicilon’s Chair and CEO Chen Chunlin, and Guotai Haitong Securities’ Chief Flobal Healthcare Analyst Yu Wenxin.

### Related Stocks

- [09995.HK](https://longbridge.com/en/quote/09995.HK.md)
- [688192.CN](https://longbridge.com/en/quote/688192.CN.md)
- [688202.CN](https://longbridge.com/en/quote/688202.CN.md)
- [688331.CN](https://longbridge.com/en/quote/688331.CN.md)
- [09969.HK](https://longbridge.com/en/quote/09969.HK.md)
- [688428.CN](https://longbridge.com/en/quote/688428.CN.md)

## Related News & Research

- [RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products](https://longbridge.com/en/news/297779978.md)
- [RemeGen authorizes up to RMB 2.5 billion in self-owned funds for wealth management products](https://longbridge.com/en/news/297774948.md)
- [CTT Pharmaceutical Holdings CEO Ryan Khouri acquires 3,000 common shares valued at $147](https://longbridge.com/en/news/297819057.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)
- [RemeGen files board, board committee member list with disclosure responsibilities](https://longbridge.com/en/news/296803857.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**